Marc Beer Is The Current Chairman Of LumeNXT, Inc.

Marc Beer is a successful entrepreneur and business man in the United States and an investor as well who ventures majorly me the healthcare sector. He is a native of Dallas and studied his undergraduate studies at Miami University where he earned his bachelor’s degree in Business Administration. When he finished his studies, Marc Beer started practicing his career by working is some organizations. , marc is also an entrepreneur, and he owns a company in the United States which he runs smoothly. He is also an excellent leader with good managerial skills which helps him in running companies smoothly.


Mark Beer has worked in many companies including Genzyme Therapeutics Worldwide where he was employed as the Leader of Global Marketing. Prior to working at Genzyme, Marc was serving at Sanofi Company as the Global Marketing leader from the year 1996 to the year 2000. Marc has also worked at a company known as Biostar. He is also remembered for working at Viacell Company as the top firm’s executive Officer. Marc is a highly experienced business professional who assumed top managerial positions in many companies, and this enabled him to run his company smoothly.


Marc Beer has spent more than 20 years in the health industry developing and commercializing the biotechnology and pharmaceutical industry. Despite the fact, Beer is not a professional in health, but he plays an essential role in the development of the industry in the United States. He is also charitable and is passionate about giving back to the community. He strives to improve the living standards of people especially women living in Boston and Dallas. Currently, he owns a pharmaceutical firm called Renovia Inc, company which is based in Dallas.


On April 2nd this year, Marc Beer became part of the Board of Directors as the chairman at LumeNXT Inc. The company is a private firm which mainly focuses on developing a surgical illumination line which is proprietary with the aim of reducing invasive surgeries. The company uses modern technology in carrying to surgeries. Marc is humbled to work for hand in hand with the group of and engineers medical officers who are aimed at providing cost effective and safe operations to patients. He assures the company to demonstrate high levels of professionalism in running the company and helping it realize its goals.


Since Marc has spent many years in the pharmaceutical and biotechnology industry, he is conversant with all the challenges facing the industry. He will try his level best to ensure that the company can overcome the challenges and achieve its goals as well as scaling to greater heights. Marc is a vital person in the company. Learn more:


“Marc Beer’s women’s health startup raises $42 million “

Women around the world suffer from numerous health conditions that severely affect the quality of life that they live. Sadly, some of these medical conditions have been neglected by the biopharma companies for one reason or another. One man, Marc Beer, an experienced executive in the pharmaceutical sector and entrepreneur is looking to change the current situation in women’s health care. Through his biopharma start-up Renovia – based in Boston – Marc is looking to finding medical solutions to some of the most chronic health issues faced by women around the world.


Raising funds for the course


Recently, Marc Beer was out and about rallying for funds to further the good course of his start-up looking to not only improve women’s health but also bring happiness to communities. In his funds rallying campaign, Marc was very successful. He managed to raise a total of $42 million in funding to finance Renovia’s operations. The main focus for the company of late has been finding therapeutic and diagnostic solutions for the notorious pelvic floor disorders especially urinary incontinence. Reliable statistics indicate that not less than 250 million women from around the globe suffer from this dreaded condition.


The Renovia CEO raised a total of $32 million through Series B funding, and the additional $10 million came from venture debt. Marc Beer successfully got on board some of the most seasoned health sector investors in his Series B round funding to raise the $32 million. A healthcare-focused investment firm, Longwood Fund which had also earlier invested in Renovia was part of the Series B round. Other investors were Ascension Ventures from Missouri and Perspective Advisors from New York.


The funding raised will be dedicated to coming up with the second generation of the Leva devices. Additionally, there are three other break-through devices in the works at Renovia which these funds will play a significant role in their development. Making this funding announcement, Marc Beer mentioned that his company was very grateful for the support of its investors. He added that his company would keep delivering new treatments for pelvic disorders as their knowledge on it expands through research.


About Marc Beer


Marc Beer is the co-founder and Chief Executive Officer of the Boston based biopharma start-up Renovia. This pharmaceutical entrepreneur has over two decades of experience as an executive in the medical sector. Marc’s area of specialization has been the development and commercialization of break-through biotechnology devices and pharmaceutical diagnostics. Through his start-up Renovia, Marc hopes to help millions of women around the world living with pelvic disorders live normal lives. The Leva device (first edition) has significantly made this possible, and he hopes with its second edition things will even get better. Learn more:


Jeff Aronin: A Pioneer in the Biotechnology Sector

Paragon Biosciences is a company that invests in innovative biotechnology companies. The goal of Paragon is to build up companies that can discover treatments for rare and previously untreatable diseases. Paragon has had 13 new drugs approved by the FDA in the past 10 years. Some of the investment partners for Paragon include Fidelity Investments, Diaderm, Debra Austria, and Valor Equity Partners.

Castle Creek Pharmaceuticals (CCP) is a Paragon portfolio company specializing in finding treatments for rare dermatologic diseases. The company has created numerous innovative drugs and therapies that have the potential to treat many of these diseases.

Harmony Biosciences is another portfolio company dedicated to finding cures and treatments for patients with sleep and central nervous system problems.

Jeff Aronin assumed the role of Chairman and CEO of Paragon Biosciences in 2010. He also is the chairman of several successful Paragon portfolio companies. Jeff Aronin founded Ovation Pharmaceuticals in 2000 and served as that company’s president and CEO until 2009. Lundbeck, Inc. acquired Ovation Pharmaceuticals in 2009 and Jeff Aronin stayed on as the CEO and president during the merger. Jeff Aronin has over 20 years of experience in creating biotechnology companies (Reporterexpert). He is highly respected in the bioscience industry because of his vast contributions and knowledge. Jeff also mentors aspiring entrepreneurs in the field.

Jeff Aronin is dedicated to philanthropy and supports numerous non-profit organizations such as the Susan G. Komen Foundation, the Liver Life Challenge, Juvenile Diabetes, the Teaching Tolerance, the Jewish United Fund, the Boys and Girls Club of Chicago, and the Chicago Parks Foundation.

Jeff has also received countless awards throughout his career that include: the 2017 Weizmann Leadership Award, Buyouts Magazine “Deal of the year in 2010,” Epilepsy Foundation of Chicago Rovner Award in 2007, and the Holocaust Museum and Education Center’s Humanitarian Award in 2010. Despite his success, Jeff Aronin will not be satisfied until treatments are found for all untreatable diseases.